SAPROPTERIN DIHYDROCHLORIDE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SAPROPTERIN DIHYDROCHLORIDE (SAPROPTERIN DIHYDROCHLORIDE).
Sapropterin dihydrochloride is a synthetic form of tetrahydrobiopterin (BH4), an essential cofactor for phenylalanine hydroxylase, tyrosine hydroxylase, and tryptophan hydroxylase. It enhances residual phenylalanine hydroxylase activity in patients with phenylketonuria (PKU) who are responsive to BH4, thereby reducing phenylalanine levels.
| Metabolism | Sapropterin is primarily metabolized in the liver via reduction by dihydropteridine reductase (DHPR) and oxidation by quinonoid dihydropteridine reductase. Minor pathways include glucuronidation and renal excretion of unchanged drug. |
| Excretion | Primarily renal, with 70-80% of the dose excreted unchanged in urine; small amount via feces (<10%) and biliary elimination is negligible. |
| Half-life | Terminal elimination half-life of 6-9 hours in adults and 6-7 hours in pediatric patients, supporting twice-daily dosing. |
| Protein binding | Approximately 96-99% bound to plasma proteins, mainly albumin. |
| Volume of Distribution | Apparent volume of distribution about 0.5 L/kg, suggesting distribution into total body water. |
| Bioavailability | Oral bioavailability of approximately 50-60% (range 40-65%) due to first-pass metabolism. |
| Onset of Action | Oral: 2-4 hours for reduction in blood phenylalanine levels. |
| Duration of Action | Approximately 24 hours, maintaining phenylalanine reduction with twice-daily dosing. |
Oral: 10 mg/kg once daily, then titrate based on response up to 20 mg/kg once daily; maximum dose 20 mg/kg daily.
| Dosage form | POWDER |
| Renal impairment | No specific dose adjustment guidelines; caution in severe renal impairment (CrCl <30 mL/min) due to limited data. |
| Liver impairment | No specific adjustment for hepatic impairment; use caution in severe hepatic disease. |
| Pediatric use | Same weight-based dosing as adults: 10 mg/kg once daily initially, titrate to 20 mg/kg once daily; safety and efficacy not established in children <4 years. |
| Geriatric use | No specific geriatric dose adjustments; monitor renal function as age-related decline may affect clearance. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SAPROPTERIN DIHYDROCHLORIDE (SAPROPTERIN DIHYDROCHLORIDE).
| Breastfeeding | Unknown if sapropterin is excreted in human milk. No M/P ratio available. Consider developmental benefits of breastfeeding versus maternal need for sapropterin and potential adverse effects on the infant. Caution advised. |
| Teratogenic Risk | Sapropterin dihydrochloride is FDA pregnancy category C. Animal studies showed embryotoxicity and fetal malformations at doses higher than human therapeutic doses. No adequate human studies in pregnant women. Risk cannot be ruled out; use only if benefit outweighs risk. First trimester: potential for teratogenicity based on animal data. Second and third trimesters: potential for fetal harm based on animal data; monitor fetal growth and amniotic fluid volume. |
■ FDA Black Box Warning
None
| Serious Effects |
["Known hypersensitivity to sapropterin or any excipient in the formulation"]
| Precautions | ["Hypersensitivity reactions including anaphylaxis have been reported","Potential for metabolic disturbances in patients with phenylketonuria; monitor blood phenylalanine levels","Risk of gastrointestinal disturbances (e.g., diarrhea, abdominal pain)","May interfere with certain laboratory assays (e.g., urinary catecholamine measurements)","Not recommended for use in patients with known hypersensitivity to any component of the formulation"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal phenylalanine levels regularly to maintain therapeutic range. Fetal monitoring: ultrasound for growth and amniotic fluid volume; consider fetal echocardiography if maternal phenylalanine levels are elevated. |
| Fertility Effects | No adequate studies on fertility in humans. Animal studies showed no effect on fertility at doses up to 10 times the human dose. However, uncontrolled phenylketonuria (PKU) may impair fertility; maintaining metabolic control with sapropterin may improve fertility outcomes. |